Cardiogenetics January 12, 2026
We already know that loss or mutation in genes can lead to increased cardiovascular risk or even cause some diseases, but what about losing a whole chromosome? New research in JACC suggests that men who lose pieces of their Y chromosome as they age could be at greater risk of heart attacks. Researchers measured the […]
Cardiology Testing January 8, 2026
A new registry analysis out of Japan suggests we may be able to simplify how we classify heart failure frailty without losing accuracy, allowing us to screen for HF mortality risk in faster and more practical ways. To see how CFS stacks up against comprehensive physical testing, researchers categorized 3.9k patients hospitalized with HF into […]
Cardiology Pharmaceuticals January 5, 2026
After years of dedicated research and careful science, Cytokinetics’ aficamten (Myqorzo) is officially FDA approved for obstructive hypertrophic cardiomyopathy, marking the company’s first-ever regulatory approval and ending BMS mavacamten’s reign as the only oHCM treatment. The FDA’s decision stemmed from the SEQUOIA-HCM trial, which demonstrated aficamten’s efficacy over 24 weeks in symptomatic obstructive HCM patients […]